RYZB NASDAQ
RayzeBio, Inc. Common Stock
1W: +0.0%
1M: +0.6%
3M: +143.2%
$62.49
Last traded 2024-03-06 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$325M
+50.1% ▲
Total Liabilities
$436M
+60.9% ▲
Shareholders Equity
-$111M
-103.9% ▼
Cash & Investments
$296M
+48.7% ▲
Total Debt
$11M
+16.7% ▲
Net Debt
-$119M
-185.7% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| — Assets — | |||
| Cash | $144M | $51M | $129M |
| Short-Term Investments | $3M | $149M | $167M |
| Cash & ST Investments | $147M | $199M | $296M |
| Net Receivables | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 |
| Other Current Assets | $211K | $3M | $4M |
| Total Current Assets | $147M | $202M | $300M |
| Property, Plant & Equip. | $1M | $14M | $24M |
| Goodwill & Intangibles | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 |
| Other Non-Current Assets | $135K | $385K | $347K |
| Total Non-Current Assets | $1M | $14M | $25M |
| Total Assets | $148M | $216M | $325M |
| — Liabilities — | |||
| Accounts Payable | $176K | $1M | $3M |
| Short-Term Debt | $763K | $2M | $1M |
| Deferred Revenue | $0 | $0 | $0 |
| Other Current Liabilities | $564K | $3M | $7M |
| Total Current Liabilities | $2M | $6M | $10M |
| Long-Term Debt | $0 | $7M | $9M |
| Other Non-Current Liab. | $150M | $258M | $416M |
| Total Non-Current Liabilities | $150M | $265M | $426M |
| Total Liabilities | $151M | $271M | $436M |
| — Equity — | |||
| Common Stock | $1K | $2K | $2K |
| Retained Earnings | -$7M | -$55M | -$130M |
| Accumulated OCI | -$1K | -$239K | -$553K |
| Total Stockholders Equity | -$3M | -$55M | -$111M |
| Total Liabilities & Equity | $148M | $216M | $325M |
| — Key Metrics — | |||
| Total Debt | $763K | $9M | $11M |
| Net Debt | -$143M | -$42M | -$119M |
| Total Investments | $3M | $149M | $167M |